Literature DB >> 28249660

Transitioning from HPV 101 to HPV 202.

Warner K Huh1, Richard Guido2.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28249660      PMCID： PMC5545792          DOI： 10.1016/j.ajog.2016.12.009

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN： 0002-9378            Impact factor:   8.661


× No keyword cloud information.
  14 in total

1.  Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance.

Authors:  Warner K Huh; Kevin A Ault; David Chelmow; Diane D Davey; Robert A Goulart; Francisco A Garcia; Walter K Kinney; L Stewart Massad; Edward J Mayeaux; Debbie Saslow; Mark Schiffman; Nicolas Wentzensen; Herschel W Lawson; Mark H Einstein
Journal:  J Low Genit Tract Dis       Date:  2015-04       Impact factor: 1.925

2.  ACOG Practice Bulletin Number 131: Screening for cervical cancer.

Authors: 
Journal:  Obstet Gynecol       Date:  2012-11       Impact factor: 7.661

3.  Similar Risk Patterns After Cervical Screening in Two Large U.S. Populations: Implications for Clinical Guidelines.

Authors:  Julia C Gage; William C Hunt; Mark Schiffman; Hormuzd A Katki; Li A Cheung; Orrin Myers; Jack Cuzick; Nicolas Wentzensen; Walter Kinney; Philip E Castle; Cosette M Wheeler
Journal:  Obstet Gynecol       Date:  2016-12       Impact factor: 7.661

4.  Management of women with human papillomavirus persistence: long-term follow-up of a randomized clinical trial.

Authors:  Kristina Elfgren; K Miriam Elfström; Pontus Naucler; Lisen Arnheim-Dahlström; Joakim Dillner
Journal:  Am J Obstet Gynecol       Date:  2016-11-05       Impact factor: 8.661

5.  Expression of p16INK4A in cervical precancerous lesions that is unlikely to be preventable by human papillomavirus vaccines.

Authors:  Suguna Badiga; Michelle M Chambers; Warner Huh; Isam-Eldin A Eltoum; Chandrika J Piyathilake
Journal:  Cancer       Date:  2016-08-01       Impact factor: 6.860

6.  Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement.

Authors:  Virginia A Moyer
Journal:  Ann Intern Med       Date:  2012-06-19       Impact factor: 25.391

7.  Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence.

Authors:  Susanne K Kjær; Kirsten Frederiksen; Christian Munk; Thomas Iftner
Journal:  J Natl Cancer Inst       Date:  2010-09-14       Impact factor: 13.506

Review 8.  Virtues and Weaknesses of DNA Methylation as a Test for Cervical Cancer Prevention.

Authors:  Attila T Lorincz
Journal:  Acta Cytol       Date:  2016-11-03       Impact factor: 2.319

9.  Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test.

Authors:  Thomas C Wright; Mark H Stoler; Catherine M Behrens; Abha Sharma; Guili Zhang; Teresa L Wright
Journal:  Gynecol Oncol       Date:  2015-01-08       Impact factor: 5.482

Review 10.  Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening.

Authors:  Thomas C Wright; Mark Schiffman; Diane Solomon; J Thomas Cox; Francisco Garcia; Sue Goldie; Kenneth Hatch; Kenneth L Noller; Nancy Roach; Carolyn Runowicz; Debbie Saslow
Journal:  Obstet Gynecol       Date:  2004-02       Impact factor: 7.661
View more
  1 in total

Review 1.  Advances in technologies for cervical cancer detection in low-resource settings.

Authors:  Kathryn A Kundrod; Chelsey A Smith; Brady Hunt; Richard A Schwarz; Kathleen Schmeler; Rebecca Richards-Kortum
Journal:  Expert Rev Mol Diagn       Date:  2019-08-01       Impact factor: 5.225
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.